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965 and 969. Recent epidemiologic, histologic, and molecular studies suggest thatthe pathogenesis of degenerative disease of the native aortic valveresembles that of atherosclerosis.1-3 The initial aortic valve lesion,valve sclerosis, is related to infiltration and oxidation of lipopro-teins similar to that seen in atherosclerosis.2,3 Calcification, one ofthe principal features of degenerative disease of the native aortic
valve, is also present in atherosclerotic plaques.2,3 Not surprisingly, retrospective
studies showed an association between risk factors for coronary artery disease, such
as male sex, cigarette smoking, high blood pressure, diabetes, and hyperlipidemia,
and progression of aortic valve stenosis.4 However, a recent prospective, popula-
tion-based epidemiologic study showed no correlation between coronary artery risk
factors and the rate of progression of aortic stenosis.5
What many studies have shown more consistently is that treatment with 3-hy-
droxy-3-methyl-glutamyl coenzyme A reductase inhibitors (statins) reduces the rate
of progression of aortic valve stenosis.4-7 In most studies the slower rate of
calcification of the aortic cusps produced by statins did not appear directly related
to the reduction of serum cholesterol level but rather caused by its pleiotropic
effects.5-7 Statins affect a multitude of cellular functions: they increase production
of nitric oxide by endothelial cells, reduce inflammatory reactions, decrease secre-
tion of metalloproteins and osteopontin by macrophages, stabilize atherosclerotic
plaques, prevent thrombus formation, and have many other less defined effects, such
as reducing the risk of dementia.8,9
Calcification of the native aortic cusps is a complex and poorly understood
process, but it appears to be related to inflammation, infiltration of lipoproteins, and
ossification.2,3,10,11 Statins probably delay calcification of the native aortic cusps by
reducing inflammation and decreasing the deposition of lipoproteins and ossifica-
tion, as they do in coronary arteries.8,12 However, the notion that coronary artery
risk factors increase the risk of aortic valve stenosis remains controversial.5,6
The pathogenesis of calcification of bioprosthetic heart valves is even less well
understood than that of the native aortic valve. Clinical experience with biopros-
thetic heart valves far exceeds the scientific knowledge of the interactions between
the host and the glutaraldehyde-fixed tissue that makes up the cusps of a biopros-
thetic valve. Calcification is the principal cause of failure of first-generation bio-
prosthetic heart valves, and young age is the single most important determinant of
calcification. The mechanism of accelerated calcification in young patients remains
largely unknown. It might involve an immune-mediated reaction and an increased
adsorption of proteins related to bone formation.13,14 The clinical observation that
prolonged corticosteroid therapy restricts calcification of bioprosthetic valves in
young patients corroborates the notion that immune reaction might play a role in
calcific degeneration.15,16 These findings suggest that the cross-links between glu-
taraldehyde and certain immunogenic proteins in the xenograft tissue might be
incomplete or short lived. Indeed, it has been shown experimentally that valves
stored in glutaraldehyde solutions for a prolonged period are less likely to calcify
than those implanted soon after fixation.17 Another interesting finding on calcifica-
tion of bioprosthetic valves is that removal of lipids with certain solvents, such as
alcohol, mitigates calcification in experimental animals.18 Newer porcine and peri-
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cardial bioprosthetic valves are treated with various agents
that are effective in reducing calcification of the cusps, and
the failure mode of these newer valves might not be the
same as in first-generation bioprostheses. Finally, mechan-
ical stress also plays an important role in bioprosthetic valve
durability. Indeed, bioprosthetic valves are more durable in
the aortic position than they are in the mitral position. Valve
and stent design is important to minimize mechanical stress
on the cusps, and that is one of the reasons why the Edwards
Perimount valve (Edwards Lifesciences, Irvine, Calif) has
proved to be more durable than the Ionescu-Shiley pericar-
dial valve (Shiley, Inc, Irvine, Calif). Inadequate stent de-
sign was probably the main reason the Hancock pericardial
valve failed prematurely, and the manufacturer (Medtronic,
Inc, Minneapolis, Minn) removed it from the market soon
after its introduction.19
In this issue of the Journal, there are 2 articles on
bioprosthetic heart valve failure and coronary artery risk
factors.19,20 Nollert and colleagues19 attempted to establish
a relationship between premature failure of the Hancock
pericardial valve and risk factors for atherosclerosis. Unfor-
tunately, the study was flawed from several important per-
spectives. First, risk factors for atherosclerosis were hope-
lessly confounded with the poorly designed pericardial heart
valve. Although it might be argued that the risk factors
identified were independent of the bad valve, it is impossi-
ble to discern whether the risk factors for atherosclerosis
would have had the same association in other types of
bioprostheses. Second, there is no clinical, biologic, or
sociologic rationale for using 57 years of age as a cutoff
point to define an elderly population. This cutoff point was
one of convenience only because it defined the median age
of the population. Third, the results in Table 1 of that article
are only valid if all survivors were followed up at the same
time (eg, within a 3-month interval). The authors did not
provide the risk ratios (RRs) or confidence intervals (CIs)
for the independent predictors of reoperation. The rationale
for leaving hypertension out of the multivariable models is
inappropriate. Finally, the use of reoperation as an end point
is potentially biased because of patient selection. A more
appropriate outcome would have been to use primary tissue
failure at reoperation, autopsy, or echocardiographic evalu-
ation. Elderly patients might not be offered reoperation at
the same rate as younger patients.
The study by Farivar and Cohn20 did not corroborate all
the findings by Nollert and colleagues19 but also suggests
that cholesterol plays a role in valve failure of a first-
generation porcine bioprosthesis. Although the difference in
cholesterol levels between the 2 groups was statistically
significant, the mean cholesterol value in both groups was
within the normal range. No other coronary artery risk
factors were found to be associated with an increased risk of
bioprosthetic heart valve failure.
In a Cox regression analysis of 653 patients without
coronary artery disease who underwent aortic valve replace-
ment with the Hancock I bioprosthesis at Stanford Univer-
sity between 1970 and 1982 (data provided by Dr D. C.
Miller), the only independent predictor of reoperation was
young age (RR for age, 0.95; 95% CI, 0.94-0.96; P .001).
Hyperlipidemia was not a significant predictor in this group
(P .5). We also constructed 2 similar age-defined cohorts,
using the age cutoff point of the study by Nollert and
colleagues.19 In the younger patients (age 58 years), the
independent predictors of reoperation were age (RR, 0.96;
95% CI, 0.94-0.98; P  .001) and male sex (RR, 1.79; 95%
CI, 1.0-3.1; P  .037). In this cohort hyperlipidemia was
not a significant predictor (P  .7). In the older patients age
was the only independent predictor of reoperation (RR,
Figure 1. Freedom from reoperation after aortic valve replace-
ment with the Hancock I bioprosthesis in patients with normal
and increased cholesterol levels (Stanford University data).
Figure 2. Freedom from reoperation after aortic valve replace-
ment with various bioprosthetic valves in patients with normal
and increased cholesterol levels (Toronto General Hospital data).
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0.93; 95% CI, 0.9-1.0; P  .036). Hyperlipidemia was not
a predictor (P  .9). Figure 1 depicts the freedom from
reoperation in patients with normal or increased cholesterol
levels after aortic valve replacement with the Hancock I
bioprosthesis.
We performed a Cox regression analysis for reoperation
in 913 patients, including those with coronary artery dis-
ease, who underwent aortic valve replacement after 1990 at
the Toronto General Hospital (Hancock II, n  426; Car-
pentier-Edwards Perimount, n  215; Toronto SPV, n 
272 [St Jude Medical, Inc, St Paul, Minn]). The only sig-
nificant independent predictor of reoperation was age (RR,
0.95; 95% CI, 0.92-0.97; P  .001), confirming previous
findings that younger patients are more likely to undergo
reoperation. Not significant in this model were smoking,
hyperlipidemia, sex, renal insufficiency, hypertension, or
diabetes. Figure 2 depicts the freedom from reoperation and
hyperlipidemia.
Because of numerous confounding factors, neither the
data of Nollert and colleagues,19 the data of Farivar and
Cohn,20 our analysis of the Stanford University data, nor our
own data prove or disprove that patients with risk factors for
atherosclerosis have accelerated bioprosthetic valve failure.
In our patients with risk factors for atherosclerosis, it is
possible that the probability of valve failure was reduced
because most of them were taking statins.
The hypotheses that risk factors for coronary artery dis-
ease might accelerate the degeneration of bioprosthetic
heart valves and that statins might reduce degeneration are
interesting and provocative and certainly deserve further
study.
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